24 November 2022
AlphaFill: filling in the blanks in protein structure prediction
The development of tools like AlphaFold and RoseTTAfold, and more recently of the ESM Metagenomic Atlas and OmegaFold, was a gamechanger in the field of 3D protein structure prediction. However, for many proteins a pivotal piece to the puzzle was still lacking, as most proteins do not function without specific cofactors. New work by the group of Oncode Investigator Anastassis Perrakis at the Netherlands Cancer Institute literally fills this void and brings AlphaFill into the picture. Their work was published today in Nature Methods.
22 November 2022
Tineke Lenstra joins the EMBO Young Investigator Programme
EMBO just announced 24 life scientists as the newest members of the EMBO Young Investigator Programme. One of the new members is Oncode Investigator Tineke Lenstra (Netherlands Cancer Institute), with her project on understanding transcriptional bursting in single cells. The Young Investigator Programme supports excellent group leaders who have been in independent positions for less than four years and have an excellent track record of scientific achievements.
18 November 2022
Oncode Institute welcomes Marvin Tanenbaum to the Research Management Committee
We are pleased to welcome Oncode Investigator Marvin Tanenbaum (Hubrecht Institute) to Oncode’s Research Management Committee (RMC). Marvin will replace Oncode Investigator Thijn Brummelkamp (NKI), who was part of the RMC for 4 years.
19 October 2022
Ruben van Boxtel receives prestigious NYSCF Robertson Stem Cell Investigator Award
The NYSCF Robertson Stem Cell Investigator Award was awarded in New York today to Oncode Investigator Ruben van Boxtel. Van Boxtel, research group leader at the Princess Máxima Center for Pediatric Oncology, will use the award to accelerate his research on the role of stem cells in the development and eventual prevention of adverse late effects in children cured of cancer. In addition to a $1.5 million prize for his research, Van Boxtel joins a network with other leading researchers in the field of stem cell biology and regenerative medicine.
In the spotlight
25 April 2022
Interview on Oncode-PACT: De-risking the preclinical phase
Although Dutch fundamental cancer research is among the world’s best, findings in this area rarely result in viable cancer medicines. How should this be improved? Oncode’s Managing Director Alain Kummer, Oncode Business Development expert Emil Pot and Friso Smit, business development manager of the Utrecht Science Park, reflect on this issue, with reference to the Oncode-PACT* Growth Fund proposal. They co-created this proposal with many other stakeholders.
10 October 2022
First step towards precision medicine for sarcoma using mini tumors
The team of Oncode Investigator Jarno Drost together with other scientists at the Princess Máxima Center have cultured organoids from rhabdomyosarcoma, an aggressive soft tissue tumor, for the first time. The organoids, 3D mini tumors grown in the lab, mimic the genetic and molecular abnormalities much better than the research models used until now.
5 October 2022
The next frontiers in cancer vaccines: when academia’s and industry’s bright minds get together
During the 3rd edition of the Biotech Wednesday Event, co-organized by HollandBIO and Oncode Institute, academia and industry came together to discuss the past, present and future of therapeutic cancer vaccines. In a packed Pakhuis de Zwijger, the brightest scientists and industry leaders in the cancer vaccine development shared their research and new developments including an outlook on the future.
19 September 2022
Meeting researchers’ needs: Advanced workshop Preclinical tumor immune models for therapeutic discovery and validation
With more than a hundred participants covering a broad community interested in the immuno-oncology field, this successful advanced workshop featured an exciting programme.
Scroll for more